Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Jaguar Health (JAGX) over the last 11 years, with Q3 2025 value amounting to -$134000.0.

  • Jaguar Health's Gains from Investment Securities rose 1829.27% to -$134000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $163000.0, marking a year-over-year increase of 11499.54%. This contributed to the annual value of $336000.0 for FY2024, which is 2380.95% down from last year.
  • As of Q3 2025, Jaguar Health's Gains from Investment Securities stood at -$134000.0, which was up 1829.27% from -$22000.0 recorded in Q2 2025.
  • Jaguar Health's Gains from Investment Securities' 5-year high stood at $1.2 million during Q2 2022, with a 5-year trough of -$2.1 million in Q4 2022.
  • In the last 5 years, Jaguar Health's Gains from Investment Securities had a median value of -$18500.0 in 2021 and averaged $3222.2.
  • In the last 5 years, Jaguar Health's Gains from Investment Securities soared by 650000.0% in 2022 and then tumbled by 35777.78% in 2023.
  • Jaguar Health's Gains from Investment Securities (Quarter) stood at $1.1 million in 2021, then crashed by 282.5% to -$2.1 million in 2022, then soared by 127.61% to $573000.0 in 2023, then plummeted by 99.13% to $5000.0 in 2024, then plummeted by 2780.0% to -$134000.0 in 2025.
  • Its Gains from Investment Securities was -$134000.0 in Q3 2025, compared to -$22000.0 in Q2 2025 and $341000.0 in Q1 2025.